National Academies Press: OpenBook
« Previous: Appendix C: Statement of Task
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

D

Registered Attendees

Olu Adeniyi

Food and Drug Administration

Russ Altman

Stanford University

Margaret Anderson

FasterCures

John Aquino

Bloomberg BNA

Hugh Auchincloss

National Institute of Allergy and Infectious Diseases

Aris Baras

Regeneron Pharmaceuticals

John Baras

University of Maryland

Miriam Bayes

Thomson Reuters

Robert Beckman

Georgetown University Medical Center

Adam Berger

Department of Health and Human Services

Gouri Shankar Bhattacharyya

Fortis Hospital

Rebecca Blanchard

Merck & Co., Inc.

Bruce Blumberg

Kaiser Permanente

Kimberly Boucher

Inova Health System

Chas Bountra

University of Oxford

Khaled Bouri

U.S. Food and Drug Administration

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

Linda Brady

National Institute of Mental Health

Joel Brill

Predictive Health LLC

PJ Brooks

National Center for Advancing Translational Sciences

Apryl Brown

American Public Health Association Genomics Forum

Tara Burke

Association for Molecular Pathology

Colleen Campbell

University of Iowa

Robert Campbell

Brown University

Lon Cardon

GlaxoSmithKline

John Carulli

Biogen

Ann Cashion

National Institute of Nursing Research

Sohini Chowdhury

The Michael J. Fox Foundation for Parkinson’s Research

Charles Cywin

National Institute of Neurological Disorders and Stroke

Andrew Dahlem

Eli Lilly and Company

Mark Daly

Massachusetts General Hospital

Susan Delaney

Coriell Institute for Medical Research

Joe Donahue

GeneDx

Michael Dougherty

American Society of Human Genetics

Erin Durkin

Inside Health Policy

Meg Ehm

GlaxoSmithKline

Raith Erickson

Independent

Lynn Etheredge

Rapid Learning Project

Greg Feero

Journal of the American Medical Association

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

Caroline Fox

Merck Research Laboratories

Steven Galson

Amgen Inc.

Michael Garvin

AstraZeneca

Taylor Gilliland

National Center for Advancing Translational Sciences

Geoffrey Ginsburg

Duke University

Tina Grande

Healthcare Leadership Council

Christian Grimstein

U.S. Food and Drug Administration

Jill Hagenkord

23andMe

Jennifer Hall

University of Minnesota

Erin Hauenstein

Northrop Grumman

Heonia Hillock

Inova Health System

Carolyn Hoban

Hartford Hospital

Arthur Holden

International Serious Adverse Event Consortium

William Hoos

Pancreatic Cancer Action Network

Lynn Hudson

Critical Path Institute

Sally John

Biogen

Brett Johnson

StoneFace Ventures

Robert Karp

National Institute of Diabetes and Digestive and Kidney Diseases

Marina Kozak

Friends of Cancer Research

Audrey Kusiak

Department of Veterans Affairs

Joan Lakoski

American Association of Colleges of Pharmacy

Katherine Lambertson

Genetic Alliance

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

David Lanfear

Henry Ford Hospital

Debra Leonard

University of Vermont Medical Center

Sharon Liang

Food and Drug Administration

Klaus Lindpaintner

Pfizer Inc.

Bolan Linghu

Pfizer Inc.

Katrina Loomis

Pfizer Inc.

Lynn Lund

Cogstate

Lynn Matrisian

Pancreatic Cancer Action Network

Robert McCormack

Janssen Oncology

Shelly Menolascino

Washington Square Psychiatry and Transcranial Magnetic Stimulation

Melissa Miller

Pfizer Inc.

Ron Miller

IMS Health

Adele Mitchell

Merck Research Labs

Cliona Molony

Pfizer Inc.

Bernard Munos

InnoThink Center for Research in Biomedical Innovation

Laura Nisenbaum

Eli Lilly and Company

James O’Leary

Genetic Alliance

Steve Olson

Self-Employed

John Orloff

Baxalta

Mike Pacanowski

Food and Drug Administration

Heather Pierce

Association of American Medical Colleges

Liz Powell

Government to Growth Consulting

Vicky Pratt

Association for Molecular Pathology

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

Rajesh Ranganathan

Pharmaceutical Research and Manufacturers of America

Nagarajan Rangarajan

National Institute of Neurological Disorders and Stroke

Robert Ratner

American Diabetes Association

Turna Ray

GenomeWeb

Samantha Roberts

Friends of Cancer Research

Tim Rolph

Pfizer Inc.

Mary Rubino

Rubino & McGuire Associates

Nadeem Sarwar

Eisai Inc.

Richard Scheller

23andMe

Kathryn Schubert

Society for Maternal–Fetal Medicine

Marion Schwartz

The Cholangiocarcinoma Foundation

Joan Scott

Health Resources and Services Administration

Kelly Servick

Science Magazine

Sam Shekar

Northrop Grumman

Chun-Pyn Shen

EMD Serono

Lana Skirboll

Sanofi

Fabrice Smieliauskas

University of Chicago

Brad Smith

FasterCures

Gyan Srivastava

Merck Research Laboratories

Kári Stefánsson

deCODE genetics

Mark Stewart

Friends of Cancer Research

Katie Johansen Taber

American Medical Association

Danilo Tagle

National Center for Advancing Translational Sciences

Sharon Terry

Genetic Alliance

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

Douglas Throckmorton

U.S. Food and Drug Administration

Patty Vasalos

College of American Pathologists

Hetal Vig

Rutgers Cancer Institute of New Jersey

Joseph Vockley

Inova Translational Medicine Institute

Carrie Wager

Pfizer Inc.

John Wagner

Takeda

Wes Walker

Cerner

Michael Watson

American College of Medical Genetics and Genomics

Susan L. Weiner

Children’s Cause for Cancer Advocacy

David Wholley

Foundation for the National Institutes of Health

Catherine Wicklund

National Society of Genetic Counselors

David Wierz

OCI Group

Bob Wildin

National Human Genome Research Institute

Jane Wilkinson

Broad Institute

Janet Williams

American Academy of Nursing; University of Iowa College of Nursing

Emre Yucel

University of Texas, Houston School of Public Health

Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 87
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 88
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 89
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 90
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 91
Suggested Citation:"Appendix D: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 92
Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop Get This Book
×
Buy Paperback | $45.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than $2 billion and takes 10 years to reach patients. The challenges associated with bringing new medicines to market have led many pharmaceutical companies to seek out innovative methods for streamlining their drug discovery research.

One way to increase the odds of success for compounds in the drug development pipeline is to adopt genetically guided strategies for drug discovery, and recognizing the potential benefits of collecting genetic and phenotypic information across specific populations, pharmaceutical companies have started collaborating with healthcare systems and private companies that have curated genetic bioresources, or large databases of genomic information. Large-scale cohort studies offer an effective way to collect and store information that can be used to assess gene–environment interactions, identify new potential drug targets, understand the role of certain genetic variants in the drug response, and further elucidate the underlying mechanisms of disease onset and progression.

To examine how genetic bioresources could be used to improve drug discovery and target validation, the National Academies of Sciences, Engineering, and Medicine hosted a workshop in March 2016. Participants at the workshop explored the current landscape of genomics-enabled drug discovery activities in industry, academia, and government; examined enabling partnerships and business models; and considered gaps and best practices for collecting population data for the purpose of improving the drug discovery process. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!